Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion
Not Applicable
Completed
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- Registration Number
- NCT06146309
- Lead Sponsor
- Al-Azhar University
- Brief Summary
Several studies have indicated a relation between the development of RVO and elevated intraocular pressure (IOP) and glaucoma \[9\]. Further investigations into the structural alterations in the fellow eyes of individuals with unilateral RVO have revealed that the pRNFL is thinner than in healthy eyes, suggesting that there may be systemic risk factors for both RVO and glaucoma
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- patients with unilateral BRVO
Exclusion Criteria
- History of retinal and/or optic nerve diseases involving glaucomatous optic disc, ischemic optic neuropathy, or optic neuritis.
- History of trauma, intravitreal injections, vitreoretinal surgeries, and retinal or macular lasers.
- A significant media opacity that makes it difficult to capture clear images.
- No history of diabetes and/or hypertension in those recruited as the control group
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Patients with unilateral BRVO aflibercept (2mg/0.05ml) -
- Primary Outcome Measures
Name Time Method peri-papillary retinal nerve fiber layer thickness 24 months post injection Layer of the retina. The thickness was measured by Optical Coherence Tomography
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link aflibercept treatment to pRNFL thickness changes in unilateral BRVO?
How does aflibercept compare to standard anti-VEGF therapies like ranibizumab in unilateral BRVO management?
Which biomarkers correlate with pRNFL thinning in fellow eyes of unilateral BRVO patients treated with aflibercept?
What adverse events are associated with aflibercept 2mg/0.05ml in unilateral BRVO clinical trials?
Are there combination therapies involving aflibercept that improve outcomes for unilateral BRVO and glaucoma comorbidities?
Trial Locations
- Locations (1)
Akram Fekry Elgazzar
🇪🇬Damietta, Egypt
Akram Fekry Elgazzar🇪🇬Damietta, Egypt